Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)
Innoviva's (INVA) quarterly Income from Non-Controlling Interests came in at -$36.2 million in Q3 2022, down 153.45% YoY from $67.7 million in Q3 2021, and down 277.06% on a QoQ basis from $20.4 million in Q2 2022.
Analysis
Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022) Analysis & Trends
Innoviva (INVA) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$36.2 million in Q3 2022.
- Quarterly Income from Non-Controlling Interests fell 153.45% year-over-year to -$36.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2023 was -$36.2 million (down 148.87% YoY) and the FY2022 annual result came in at $6.3 million, down 70.68% from the prior year.
- Income from Non-Controlling Interests slipped to -$36.2 million in Q3 2022, from $20.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $67.7 million in Q3 2021 to a low of -$36.2 million in Q3 2022.
- A 5-year average of $12.5 million and a median of $12.7 million in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2018 — Income from Non-Controlling Interests jumped 4128.68% — and 2022, when it sank 153.45%.
- Tracing INVA's Income from Non-Controlling Interests over 5 years: stood at $5.5 million in 2018, then surged by 118.39% to $11.9 million in 2019, then surged by 77.23% to $21.1 million in 2020, then soared by 220.55% to $67.7 million in 2021, then slumped by 153.45% to -$36.2 million in 2022.
- The last three Income from Non-Controlling Interests figures came in at -$36.2 million (Q3 2022), $20.4 million (Q2 2022), and $22.1 million (Q1 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -36.18 Mn |
| Jun 30, 2022 | 20.43 Mn |
| Mar 31, 2022 | 22.09 Mn |
| Sep 30, 2021 | 67.68 Mn |
| Jun 30, 2021 | 21.90 Mn |
| Mar 31, 2021 | 15.57 Mn |
| Dec 31, 2020 | 21.11 Mn |
| Sep 30, 2020 | 13.40 Mn |
| Jun 30, 2020 | 21.38 Mn |
| Mar 31, 2020 | 13.52 Mn |
| Dec 31, 2019 | 11.91 Mn |
| Sep 30, 2019 | 7.24 Mn |
| Jun 30, 2019 | 8.32 Mn |
| Mar 31, 2019 | 6.23 Mn |
| Dec 31, 2018 | 5.46 Mn |
| Sep 30, 2018 | 3.08 Mn |
| Jun 30, 2018 | 1.99 Mn |
| Mar 31, 2018 | 749,000.00 |
| Dec 31, 2017 | 129,000.00 |